[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100567148":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":32,"responsibleParty":51,"collaborators":29,"id":54,"slug":29,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":29,"eligibilityCriteria":59,"healthyVolunteers":55,"sex":60,"minAge":61,"maxAge":29,"enrollmentInfo":62,"targetDuration":29,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":29,"overallStatus":35,"whyStopped":29,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Navy General Hospital, Beijing","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Pola-ZR2P","EXPERIMENTAL","Patients were treated by Pola-ZR2P as Induction Therapy",[13],"Drug: Polatuzumab Vedotin, Zanubrutinib, Rituximab, Lenalidomide and Prednisone as Induction Therapy",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Polatuzumab Vedotin, Zanubrutinib, Rituximab, Lenalidomide and Prednisone as Induction Therapy","Patients were treated by Polatuzumab Vedotin(1.8mg\u002Fkg iv qd d1), Zanubrutinib(160mg po bid d1-21), Rituximab(375mg\u002Fm2 iv qd d1), Lenalidomide(25mg po qd d1-14) and Prednisone(60mg\u002Fm2 po qd d1-5) as induction therapy",[9],[9],[22],{"name":23,"affiliation":5,"role":24},"Liren Qian, PhD","PRINCIPAL_INVESTIGATOR",[26,31],{"name":23,"role":27,"phone":28,"phoneExt":29,"email":30},"CONTACT","+861066947194",null,"qlr2007@126.com",{"name":23,"role":27,"phone":29,"phoneExt":29,"email":29},[33],{"facility":34,"status":35,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Navy General Hospital","RECRUITING","Beijing","Beijing Municipality","100048","China","CN",{"type":42,"coordinates":43},"Point",[44,45],116.39723,39.9075,{"lat":45,"lon":44},[48],{"name":49,"role":27,"phone":50,"phoneExt":29,"email":30},"Liren Qian, M.D.","+861066957676",{"type":24,"investigatorFullName":52,"investigatorTitle":53,"investigatorAffiliation":5,"oldNameTitle":29,"oldOrganization":29},"Liren Qian","Associate Chief Physician, Associate Professor","100567148",false,"NCT06664411","Pola-ZR2P in Previously Untreated DLBCL","Polatuzumab Vedotin, Zanubrutinib, Rituximab, Lenalidomide and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma","Inclusion Criteria:\n\n* Pathologically confirmed Diffuse Large B Cell Lymphoma according World Health Organization (WHO) classification;\n* Patient is ≥ 18 years of age at the time of signing the informed consent form (ICF).\n* Patient must understand and voluntarily sign an ICF prior to any study-specific assessments\u002Fprocedures being conducted;\n* Patient is willing and able to adhere to the study visit schedule and other protocol requirements;\n* Patient has not received chemotherapy previously.\n* Anticipated life expectancy at least 3 months\n\nExclusion Criteria:\n\n* Active or uncontrolled infections requiring systemic treatment within 14 days before enrollment.\n* Any instability of systemic disease, including but not limited to severe cardiac, liver, kidney, or metabolic disease need therapy.\n* Pregnant or lactating women","ALL","14 Years",{"count":63,"type":64},80,"ESTIMATED","INTERVENTIONAL",[67],"PHASE2","The goal of this phase 2 trial is to test the safety and efficacy of Pola-ZR2P as induction therapy in patients with DLBCL.",[70],"Diffuse Large B-cell Lymphoma","2025-08-13",{"date":73,"type":74},"2025-08-19","ACTUAL",{"date":76,"type":74},"2024-09-24",{"date":78,"type":64},"2030-12",{"name":5,"class":6},1]